# Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct07276373/  
OnCo record `nct07276373` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Corcept Therapeutics, now recruiting.

## Summary

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07276373 by Corcept Therapeutics, with 50 participants planned, started 2026-01-16 and due to reach its primary completion in 2026-09. Interventions recorded: Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg and Nivolumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07276373
- Phase: 1/2
- Setting: A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies
- Sponsor: Corcept Therapeutics
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07276373: https://clinicaltrials.gov/study/NCT07276373

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Corcept Therapeutics](https://onco.cc/companies/corcept/)

---
JSON: https://onco.cc/api/v1/entities/nct07276373.json